Prestige Consumer Healthcare Inc. doesn’t hesitate to innovate in its marketing and extending its product lines but changing its strategy in response to large pharma firms spinning out their consumer health businesses isn’t in its plans.
Prestige Consumer Focused On ‘Smaller Categories’ As Larger Firms Change Industry Landscape
Larger consumer health firms are “looking to move-the-needle opportunities, which are big brands, big categories, different regions than we compete in as part of their business objective,” says CEO Ron Lombardi as PCH reports revenues down slightly from year-ago period at $286.3m.
More from Earnings
• By
Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."
More from Business
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.